Idiopathic Anemia of Aging (IAA)
The purpose of this trial is to examine whether Epoetin Alfa, a hormone stimulating production of red blood cells, can reverse idiopathic anemia.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Primary Purpose: Treatment
|Official Title:||Pilot Study of Epoetin Alfa in Idiopathic Anemia of Aging (IAA)|
- Response of Anemia
- To determine if there is a beneficial effect of quality of life, cognitive function, and physical function.
|Study Start Date:||August 2004|
|Study Completion Date:||May 2007|
|Primary Completion Date:||May 2007 (Final data collection date for primary outcome measure)|
As individuals become older, the frequency of anemia increases. While the cause of anemia in many cases can be determined and corrected, in a number of individuals there is no correctable cause found and the patient must live with their anemia. This is known as idiopathic anemia, and can have serious consequences for the individual. Numerous studies have demonstrated that anemia is associated with loss of energy and stamina, causing individuals to decrease their activities, which adversely affects both their sense of well-being as well as their physical strength. Losses in these areas are associated with the clinical manifestations of frailty.
The current pilot study will examine whether or not administration of Epoetin Alfa, a hormone stimulating production of red blood cells, can reverse this type of anemia. We will examine the consequences of reversing the anemia in terms of physical strength and function, cardiovascular function and sense of well-being and mental function.
In this study, individuals with anemia will be treated for six months with Epoetin Alfa following the correction of their anemia and measurements done to evaluate physical strength, performance, cardiac, mental and kidney function. At the end of treatment, individuals will be followed for an additional six months to determine whether the anemia recurs and physical function decreases.
Participation in this study is voluntary. All testing and medication received are free to the participant.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00104169
|United States, Maryland|
|Baltimore, Maryland, United States, 21225|
|Principal Investigator:||William Ershler, MD||NIA, NIH|